Observational studyJournal of neurology2026

Two-year OCT follow-up in multiple sclerosis patients on Ofatumumab shows retinal preservation over non-antiCD20 treatments.

Giacomo Greco et al.PubMed ↗Publisher ↗

No numbers read from the abstract.